Objective: To investigate the expression of LncRNA-ATB in cholangiocarcinoma and its relationship with clinicopathological parameters and prognosis. Methods: 124 patients with CCA who underwent radical resection from January 2009 to December 2013 were selected, and the removed cancer tissues and matched adjacent tissue specimens were collected. The expression of lncRNA-ATB in CCA tissues was detected by real-time reverse transcription polymerase chain reaction (RT-PCR), and the correlation between the expression of lncRNA-ATB and clinicopathological parameters and prognosis was analyzed. Results: The relative expression of lncRNA-ATB in cholangiocarcinoma tissues was 2.84±0.52, which was significantly higher than that in adjacent tissues 1.06±0.08 (P<0.05). The expression of lncRNA-ATB was not correlated with age, gender and differentiation (P>0.05), but correlated with tumor size, depth of invasion, lymphatic/vascular lesions, lymph node metastasis and UICC staging (P<0.05). Compared with the low expression group, the tumors in the high expression group of lncRNA-ATB increased significantly (P<0.05), and the infiltration depth increased significantly (P<0.05) as well. The incidence of lymphocyte infiltration, vascular infiltration and lymph node metastasis in the high expression group of lncRNA-ATB were significantly higher than those in the low expression group.The recurrence-free survival rate in the high expression group of lncRNA-ATB was significantly lower than that in the low expression group (P<0.05). Conclusion: The expression level of lncRNA-ATB is positively correlated with the malignant biological behavior of CCA, which can be used as a biomarker to judge the prognosis of CCA.
 LUMACHI F,CHIARA G,TOZZOLI R,et al.P-035 simultaneous carcinoembryonic antigen (CEA),carcinoma antigen 19-9(CA 19-9) and 125(CA-125) measurement in patients with gastric cancer (stage IA-IB):a case-control study[J].Annals of Oncology,2016,27(suppl_2):ii10-ii11.
 XUE X,YANG Y A,ZHANG A,et al.LncRNAHOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer[J].Oncogene,2016,35(21):2746-2755.
 ENGREITZ J M,HAINES J E,PEREZ E M,et al.Local regulation of gene expression by lncRNA promoters,transcription and splicing[J].Nature,2016,539(7629):452-455.
 ARUN G,DIERMEIER S,AKERMAN M,et al.Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss[J].Genes and Development,2016,30(1):34-51.
 MATOUK I J,HALLE D,RAVEH E,et al.The role of the oncofetal H19 lncRNA in tumor metastasis:orchestrating the EMT-MET decision[J].Oncotarget,2016,7(4):3748-3765.
 HU X,BAO J,WANG Z,et al.The plasma lncRNA acting as fingerprint in non-small-cell lung cancer[J].Tumor Biology,2016,37(3):3497-3504.
 DICKSON I.Hepatocellular carcinoma:a role for lncRNA in liver cancer[J].Nature Reviews Gastroenterology and Hepatology,2016,13(3):122-123.
 HUANG R,WANG X,ZHANG W,et al.Down-Regulation of LncRNA DGCR5 correlates with poor prognosis in hepatocellular carcinoma[J].Cellular Physiology and Biochemistry,2016,40(3-4):707-715.
 SUN M,NIE F,WANG Y,et al.LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2,LSD1,and DNMT1[J].Cancer Research,2016,76(21):6299-6310.
 ZHENG B,JEONG S,ZHU Y,et al.miRNA and lncRNA as biomarkers in cholangiocarcinoma (CCA)[J].Oncotarget,2017,8(59):100819-100830.
 CHEN F,LI Y,FENG Y,et al.Evaluation of antimetastatic effect of lncRNA-ATB siRNA delivered using ultrasound-targeted microbubble destruction[J].Dna and Cell Biology,2016,35(8):393-397.
 SUFARU I G,BEIKIRCHER G,WEINHAEUSEL A,et al.Inhibitors of DNA methylation support TGF-β1-induced IL11 expression in gingival fibroblasts[J].Journal of Periodontal and Implant Science,2017,47(2):66-76.
 PENG L,YUAN X,JIANG B,et al.LncRNAs:key players and novel insights into cervical cancer[J].Tumor Biology,2016,37(3):2779-2788.
 LUO S,LU J Y,LIU L,et al.Divergent lncRNAs regulate gene expression and lineage differentiation in pluripotent cells[J].Cell Stem Cell,2016,18(5):637-652.